Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones
摘要:
A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity. (c) 2007 Elsevier Ltd. All rights reserved.
Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones
摘要:
A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity. (c) 2007 Elsevier Ltd. All rights reserved.
[EN] COMPOUNDS ACTIVE TOWARDS BROMODOMAINS<br/>[FR] COMPOSÉS ACTIFS ENVERS DES BROMODOMAINES
申请人:NUEVOLUTION AS
公开号:WO2016016316A1
公开(公告)日:2016-02-04
Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
揭示了针对溴结构域的化合物,含有这些化合物的药物组合物以及这些化合物在治疗中的用途。
Bicyclic androgen and progesterone receptor modulator compounds and methods
申请人:Zhi Lin
公开号:US20050288350A1
公开(公告)日:2005-12-29
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.